NYSE:LLY 30 November 2025 - 12 December 2025

Meta description: Eli Lilly stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets.

As of mid‑day trading on December 10, 2025, Eli Lilly is changing hands at around $980 per share, down slightly on the day and just below its recent all‑time high above $1,050. That price values Lilly at roughly $930–$1,000+ billion in market cap, depending on intraday moves, placing it in the same league as mega‑cap tech giants and making it the first healthcare company ever to cross the $1 trillion mark. Reuters

As Wall Street heads into Monday’s session, Eli Lilly and Company sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning.

Eli Lilly and Company remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on drug prices.

Eli Lilly and Company is trading around $1,030–$1,040 per share on 4 December 2025, down roughly 1% on the session after slipping from about $1,046 in the previous close. Intraday, the stock has been oscillating roughly between $1,022 and $1,051. Intellectia

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025.

Eli Lilly and Company heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity drugs, and a late‑month pullback as investors digest aggressive US drug‑pricing deals and sky‑high valuations.